Hypocalcemia Management

Management

Follow Up

Monitor serum Ca for the first month
- Daily if severe hypocalcemia
- Weekly if moderate hypocalcemia
Measure serum parathyroid hormone levels, 24 hour urinary Ca within 2-4 weeks of start of therapy

Denosumab: A critical aspect of metastatic prostate cancer treatment

Prof. Bertrand Tombal, Assoc Prof. Edmund Chiong, 18 May 2022

Men with metastatic prostate cancer (mPC) have an elevated risk of skeletal complications either due to bone metastases (skeletal-related events [SREs]), or from osteoporosis induced by androgen deprivation therapy (ADT). Two key opinion leaders recently shared their perspectives on bone complications in mPC as well as the use of bone-targeted agents (BTAs) such as denosumab (Xgeva) to reduce the risk of bone complications.

Professor Bertrand Tombal

Professor of Urology

Cliniques universitaires Saint-Luc & Université catholique de Louvain

Brussels, Belgium

Associate Professor Edmund Chiong

Head, Department of Urology

National University Hospital, Singapore

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Updates in the Management of Osteoporotic Fracture Risk

Dr. Chionh Siok Bee, Dr. Charles A Inderjeeth, 29 Nov 2018

Osteoporosis is a bone condition characterized by reduced bone mass and microarchitectural deterioration of bone tissue, consequently increasing bone fragility and fracture susceptibility.¹ Despite being a major cause of death and disability, osteoporosis is significantly underdiagnosed and undertreated in Asia.² At a recent symposium supported by the Osteoporosis Society (Singapore) and organized by Amgen, local expert Dr Chionh Siok Bee presented an overview of the fracture landscape in Singapore, while internationally renowned guest speaker Dr Charles A Inderjeeth discussed the importance of identifying and managing osteoporosis fracture risk, with a focus on the role of antiresorptive agent denosumab.